Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000282912 | SCV000345423 | uncertain significance | not provided | 2016-09-06 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000282912 | SCV000884288 | uncertain significance | not provided | 2018-01-28 | criteria provided, single submitter | clinical testing | The p.Asn174Ser variant (rs145037203) was reported in one Spanish patient with Usher type I syndrome, who also carried a CDH23 variant (Jaijo 2012). This variant is listed in the Genome Aggregation Database (gnomAD) with a frequency of 0.1 percent in the Latino population (identified on 37 out of 34,418 chromosomes), and has been reported to the ClinVar database (Variation ID: 290793). The asparagine at position 174 is moderately conserved considering 12 species (Alamut v2.10) and computational analyses of the p.Asn174Ser variant on protein structure and function indicate a deleterious effect (SIFT: damaging, MutationTaster: disease causing, PolyPhen-2: possibly damaging). Altogether, there is not enough evidence to classify the p.Asn174Ser variant with certainty. |
Labcorp Genetics |
RCV000282912 | SCV001415808 | likely benign | not provided | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000282912 | SCV002568650 | uncertain significance | not provided | 2022-08-19 | criteria provided, single submitter | clinical testing | Reported with a CDH23 variant on the same allele (in cis) in a patient with Usher syndrome in published literature (Jaijo et al., 2012); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22815625, 32483926) |
Natera, |
RCV001276790 | SCV001463339 | uncertain significance | Usher syndrome type 1F | 2020-09-16 | no assertion criteria provided | clinical testing |